Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $11293.0.

  • Gain Therapeutics' Current Deferred Revenue fell 9840.5% to $11293.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11293.0, marking a year-over-year decrease of 9840.5%. This contributed to the annual value of $252211.0 for FY2024, which is 7752.41% down from last year.
  • As of Q3 2025, Gain Therapeutics' Current Deferred Revenue stood at $11293.0, which was down 9840.5% from $22685.0 recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Current Deferred Revenue peaked at $1.4 million during Q3 2023, and registered a low of $11293.0 during Q3 2025.
  • For the 5-year period, Gain Therapeutics' Current Deferred Revenue averaged around $439851.4, with its median value being $259357.5 (2021).
  • As far as peak fluctuations go, Gain Therapeutics' Current Deferred Revenue surged by 235295.58% in 2023, and later plummeted by 9840.5% in 2025.
  • Gain Therapeutics' Current Deferred Revenue (Quarter) stood at $266504.0 in 2021, then plummeted by 79.29% to $55180.0 in 2022, then surged by 1933.6% to $1.1 million in 2023, then crashed by 77.52% to $252211.0 in 2024, then tumbled by 95.52% to $11293.0 in 2025.
  • Its last three reported values are $11293.0 in Q3 2025, $22685.0 for Q2 2025, and $217841.0 during Q1 2025.